NHLBI 30 day FRN

Federal Register / Vol. 80, No. 177 / Monday, September 14, 2015 / Notices
Dated: September 9, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–23042 Filed 9–11–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Minority Health
and Health Disparities; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Minority Health and Health Disparities
Special Emphasis Panel; Technologies/
Innovations for Improving Population Health
and Eliminating Health Disparities (R41/R42,
R43/R44).
Date: October 20, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Xinli Nan, MD, Ph.D.,
Scientific Review Officer, National Institute
on Minority Health and Health Disparities,
National Institutes of Health, Scientific
Review Branch, OERA, 6707 Democracy
Blvd., Suite 800, Bethesda, MD 20892, (301)
594–7784, [email protected].

Name of Committee: Center for Scientific
Review Special Emphasis Panel—Cancer
Therapeutics.
Date: September 22, 2015.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Careen K Tang-Toth,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804, Bethesda, MD 20892, (301) 435–
3504, [email protected].
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.39–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 8, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–22985 Filed 9–11–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health

Dated: September 9, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.

Submission for OMB Review; 30-Day
Comment Request: Population
Sciences Biospecimen Catalog (PSBC)

[FR Doc. 2015–23043 Filed 9–11–15; 8:45 am]

SUMMARY:

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
tkelley on DSK3SPTVN1PROD with NOTICES

amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as

VerDate Sep<11>2014

18:15 Sep 11, 2015

Jkt 235001

Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Cancer Institute, the National Institutes
of Health, has submitted to the Office of
Management and Budget (OMB) a
request for review and approval of the
information collection listed below.
This proposed information collection
was previously published in the Federal
Register on (June 30, 2015 P.37280) and
allowed 60-days for public comment.
No public comments were received. The

PO 00000

Frm 00060

Fmt 4703

Sfmt 4703

55141

purpose of this notice is to allow an
additional 30 days for public comment.
The National Cancer Institute (NCI),
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, or request more
information on the proposed project,
contact: Danielle Carrick, Program
Director, Division of Cancer Control and
Population Sciences (DCCPS), National
Cancer Institute, 9609 Medical Center
Dr., Room 4E224, Rockville, MD 20850
or call non-toll-free number (240) 276–
6749 or Email your request, including
your address to: Danielle.Carrick@
nih.gov. Formal requests for additional
plans and instruments must be
requested in writing.
Proposed Collection: Population
Sciences Biospecimen Catalog (PSBC)
(NCI), 0925—NEW, National Cancer
Institute(NCI), National Institutes of
Health (NIH).
Need and Use of Information
Collection: This is a request for approval
of a new collection. The National
Cancer Institute (NCI) Division of
Cancer Control and Population Sciences
(DCCPS) has previously demonstrated
that approximately 60% of population
based studies funded by the division
use existing biospecimens from other
collections, and that those studies are
more cost and time efficient than
studies collecting new specimens. Yet,
it is difficult for researchers to identify
potentially appropriate sources for
biospecimens and accompanying
epidemiologic and exposure data.
Development of a searchable inventory
of population-based biospecimen
resources was a major recommendation
resulting from an NCI think tank held in
August 2013 (‘‘Utilizing Existing
Clinical and Population Biospecimen
Resources for Discovery or Validation of

E:\FR\FM\14SEN1.SGM

14SEN1

55142

Federal Register / Vol. 80, No. 177 / Monday, September 14, 2015 / Notices

Markers for Early Cancer Detection’’)
and would also be directly addressing
four of the key recommendations that
emerged in an NCI sponsored workshop
titled ‘‘Trends in 21st Century
Epidemiology: From Scientific
Discoveries to Population Health’’
(CEBP, 2013, issue 22, page 508). In
response to this, NCI DCCPS is
developing a biospecimen inventory
and online searchable catalog (or

‘‘Population Sciences Biospecimen
Catalog (PSBC)’’). The PSBC allows
scientists in the research community
and the NCI to locate specimens
appropriate for their population based
research projects. It is not NCI’s intent
to collect biospecimens; rather the
collections are descriptions of the
available data that can act as a resource
and be shared with researchers and
scientists who are interested. This

submission is via data upload to the
secure Web site in order to collect
information to manage and improve a
program and its resources for the use by
all scientists.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
80.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent

Average
time per
response
( in hours)

Total annual
burden hour

Type of respondent

Population Sciences Biospecimen Catalog Initial
Request.

Private Sector ...............

30

1

1

30

State Government ........
Private Sector ...............

30
30

1
1

1
20/60

30
10

State Government ........

30

1

20/60

10

Population Sciences Biospecimen Catalog Annual Update.

Dated: September 1, 2015.
Karla Bailey,
NCI Project Clearance Liaison, National
Cancer Institute, NIH.
[FR Doc. 2015–23027 Filed 9–11–15; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Characterization of
Risk of HIV and HIV Outcomes in the
Brazilian Sickle Cell Disease (SCD)
Population and Comparison of SCD
Outcomes Between HIV Sero-Positive
and Negative SCD (NHLBI)
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Heart, Lung, and Blood Institute
(NHLBI), the National Institutes of
Health (NIH) has submitted to the Office
of Management and Budget (OMB) a
request for review and approval of the
information collection listed below.
This proposed information collection
was previously published in the Federal
Register on June 8, 2015 (80 FR 32388)
and allowed 60-days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Institutes of
Health may not conduct or sponsor, and
the respondent is not required to
respond to, an information collection
that has been extended, revised, or
implemented on or after October 1,

SUMMARY:

tkelley on DSK3SPTVN1PROD with NOTICES

Number of
respondents

Form name

VerDate Sep<11>2014

18:15 Sep 11, 2015

Jkt 235001

1995, unless it displays a currently valid
OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: Desk Officer for NIH.
DATES: Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments or request more
information on the proposed project
contact: Simone Glynn, MD, Project
Officer/ICD Contact, Two Rockledge
Center, Suite 9142, 6701 Rockledge
Drive, Bethesda, MD 20892, or call 301–
435–0065, or Email your request,
including your address to: glynnsa@
nhlbi.nih.gov. Formal requests for
additional plans and instruments must
be requested in writing.
Proposed Collection: Characterization
of risk of HIV and HIV outcomes in the
Brazilian Sickle Cell Disease (SCD)
population and comparison of SCD
outcomes between HIV sero-positive
and negative SCD patients 0925–NEW,
National Heart, Lung, and Blood
Institute (NHLBI), the National
Institutes of Health (NIH).
Need and Use of Information
Collection: The National Heart, Lung,
and Blood Institute (NHLBI) Recipient
Epidemiology and Donor Evaluation

PO 00000

Frm 00061

Fmt 4703

Sfmt 4703

Study-III (REDS–III) program conducts
research focused on the safety of the
blood supply, the patients who are in
need of transfusions, and the
epidemiology of transfusiontransmissible infections such as human
immunodeficiency virus (HIV). Sickle
cell disease (SCD) is a blood disorder
that affects thousands of people in the
United States and Brazil. Many patients
with SCD need to be chronically
transfused with red blood cells and the
REDS–III research program has
established in Brazil a cohort of patients
with SCD to study transfusion outcomes
and infectious diseases such as HIV in
the SCD population.
Sickle cell disease predominantly
affects persons with sub-Saharan Africa
and other malaria-endemic regions
ancestry because people who carry one
sickle cell disease gene (you need 2 to
have sickle cell disease) have a survival
advantage for malaria. Sub-Saharan
Africa, where most people with SCD in
the world live, remains one of the
regions most severely affected by HIV,
with nearly 1 in every 20 adults living
with the virus. In the United States, HIV
also disproportionately affects persons
with African ancestry. Despite the
diseases’ occurrence in similar
populations and the fact that both HIV
and SCD are independent predictors of
outcomes such as stroke, there is a lack
of data to evaluate if patients with SCD
and HIV have different illnesses than
patients who have SCD- or HIV-only.
The proposed study will seek to
understand the risk of HIV in the SCD
population, describe HIV outcomes in
patients with SCD and compare SCD
complications between HIV-positive

E:\FR\FM\14SEN1.SGM

14SEN1